FDA greenlights amlodipine oral suspension to treat hypertension, CAD

Anicka Slachta | | Cardiovascular Business | Heart Health

Massachusetts-based Azurity Pharmaceuticals announced July 10 it had received FDA approval for Katerzia Oral Suspension, making the drug the first and only FDA-approved amlodipine oral suspension to hit the commercial market.

Katerzia, a calcium channel blocker, was approved to treat hypertension in adults and pediatric patients aged 6 and up, as well as coronary artery disease in adults. The 1 mg/mL solution offers a ready-to-use, liquid alternative to amlodipine that’s easier for younger patients to stomach.

“We are pleased to announce the FDA approval of Katerzia,” Neal Muni, MD, president and CEO of Azurity Pharmaceuticals, said in a statement. “The addition of Katerzia complements our existing pediatric hypertension portfolio and will strengthen the overall offering from Azurity.”

Katerzia, according to the company’s statement, will be available through an “extensive” network of pharmacies and qualified mail order service.

""
Anicka Slachta

After graduating from Indiana University-Bloomington with a bachelor’s in journalism, Anicka joined TriMed’s Chicago team in 2017 covering cardiology. Close to her heart is long-form journalism, Pilot G-2 pens, dark chocolate and her dog Harper Lee.

Related Content

FDA sued over ‘reckless and arbitrary’ semaglutide decision
FDA clears Google smartwatch tech that calls 911 when a user’s heart stops
FDA ends semaglutide shortage, closing the door on compounded Wegovy, Ozempic
FDA approves first rapid-acting insulin biosimilar for diabetes
Aspartame linked to surging insulin levels, fatty plaques and inflammation
FDA warns that smartphone-compatible diabetes devices may not work properly

Around the web

Radiology Business
The impact of Trump tariffs on iodine contrast media costs

GE HealthCare said the price of iodine contrast increased by more than 200% between 2017 to 2023. Will new Chinese tariffs drive costs even higher?

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.